Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 14
1966 26
1967 20
1968 24
1969 28
1970 39
1971 32
1972 45
1973 31
1974 28
1975 27
1976 25
1977 31
1978 37
1979 42
1980 36
1981 44
1982 43
1983 34
1984 37
1985 48
1986 31
1987 61
1988 87
1989 81
1990 90
1991 75
1992 103
1993 96
1994 101
1995 110
1996 103
1997 130
1998 166
1999 178
2000 194
2001 272
2002 275
2003 322
2004 370
2005 356
2006 387
2007 457
2008 497
2009 494
2010 618
2011 647
2012 669
2013 832
2014 869
2015 890
2016 856
2017 836
2018 829
2019 461
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

12,157 results
Results by year
Filters applied: . Clear all
Page 1
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F, et al. Expert Opin Investig Drugs 2018 - Review. PMID 29938545
INTRODUCTION: A new pharmacological class, Janus kinases (JAK) inhibitors, has been shown to be effective and safe for the treatment of inflammatory bowel diseases (IBDs). ...EXPERT OPINION: JAK inhibitors, if approved by the regulatory authorities, could represent a novel and intriguing drug class. ...
INTRODUCTION: A new pharmacological class, Janus kinases (JAK) inhibitors, has been shown to be effective and safe for the treatment of i
Inflammatory bowel disease.
Podolsky DK. N Engl J Med 2002 - Review. PMID 12167685
Systematic review: the efficacy of herbal therapy in inflammatory bowel disease.
Ng SC, et al. Aliment Pharmacol Ther 2013 - Review. PMID 23981095 Free article.
BACKGROUND: Complementary and alternative medicine (CAM), particularly herbal therapy, is widely used by patients with inflammatory bowel disease (IBD) but controlled data are limited. AIM: To systematically review the literature on the efficacy of herbal therapy in the treatment of ulcerative colitis (UC) and Crohn's disease (CD). ...
BACKGROUND: Complementary and alternative medicine (CAM), particularly herbal therapy, is widely used by patients with inflammator
[Treatment of inflammatory bowel diseases].
Gomollón F. Gastroenterol Hepatol 2015 - Review. PMID 26520192 Spanish.
In addition to immunosuppressive drugs and anti-TNF, there are a number of new options in the treatment of inflammatory bowel diseases. ...
In addition to immunosuppressive drugs and anti-TNF, there are a number of new options in the treatment of inflammatory bowel
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ, et al. Am J Gastroenterol 2011 - Review. PMID 21407187
The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. ...This systematic review is a mandate for further trials of antibiotic therapy in IBD....
The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunol …
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Bermejo F, et al. Gastroenterol Hepatol 2018 - Review. PMID 29357999
Thiopurines (azathioprine and mercaptopurine) are widely used in patients with inflammatory bowel disease. In this paper, we review the main indications for their use, as well as practical aspects on efficacy, safety and method of administration. ...Non-melanoma skin cancer, lymphomas and urinary tract tumours have been linked to thiopurine therapy. Thiopurine use is safe during conception, pregnancy and breastfeeding....
Thiopurines (azathioprine and mercaptopurine) are widely used in patients with inflammatory bowel disease. In this paper, we r …
Emerging Therapies for Inflammatory Bowel Diseases.
Khanna R and Feagan BG. Dig Dis 2016 - Review. PMID 27548692
BACKGROUND: The past decade has seen important advances in the management of chronic inflammatory bowel diseases (IBD), consisting of Crohn's disease (CD) and ulcerative colitis. ...Emerging concepts that will continue to evolve and shape the field include an increased emphasis on personalized medicine (right drug, right dose, right time) and the development of new therapeutic classes. ...
BACKGROUND: The past decade has seen important advances in the management of chronic inflammatory bowel diseases (IBD), …
Current and emerging therapeutic targets for IBD
Neurath MF. Nat Rev Gastroenterol Hepatol 2017 - Review. PMID 28144028
The introduction of immunosuppressive (such as azathioprine) and biologic agents (such as TNF blockers) has markedly reduced the need to use corticosteroids for therapy. ...This Review aims to provide a comprehensive overview about current and future therapeutic approaches for IBD therapy. Furthermore, potential mechanisms of action of these therapeutic approaches and their implications for clinical therapy in IBD are discussed....
The introduction of immunosuppressive (such as azathioprine) and biologic agents (such as TNF blockers) has markedly reduced the need to use …
A review of current evidence allied to step-up and top-down medication therapy in inflammatory bowel disease.
Salahudeen MS. Drugs Today (Barc) 2019. PMID 31250843
Inflammatory bowel disease (IBD), classified as a global disease in the 21st century, comprises Crohn's disease (CD) and ulcerative colitis (UC), and is manifested by chronic inflammation of the gastrointestinal tract of unknown etiology. The step-up approach is effective for inducing remission and controlling inflammation, whereas the top-down therapy appears to be a better solution for the maintenance of remission with an improved bowel function. ...
Inflammatory bowel disease (IBD), classified as a global disease in the 21st century, comprises Crohn's disease (CD) and ulcer
12,157 results
Jump to page
Feedback